t commonly reported adverse events were dizziness reported in three percent and fatigue, flu-like symptoms, diarrhea and cough all reported in two percent of patients. Patients with significant elevations of potassium, renal insufficiency, or diabetes associated with microalbuminuria, or who are taking potassium supplements or certain diuretics must not take eplerenone. INSPRA is also being studied for use in heart failure to determine its effect on morbidity and mortality in patients who have suffered a heart attack and have early complications of heart failure.

'"/>

Contact: Karen Sutherland
908-901-8584
MCS
30-Sep-2002

Page: 1 2
Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves EPZICOM
6. FDA approves new labelling for Seroquel in bioplar mania
7. FDA approves Enbrel to treat psoriasis
8. FDA approves Climara Pro to treat menopause symptoms
9. FDA approves new approach to schizophrenia treatment
10. FDA approves new HIV protease inhibitor, Lexiva (TM)
11. FDA approves Wellbutrin XL(TM)